UCB's Phase III lupus failure casts further shadow over field
This article was originally published in Scrip
UCB's leading lupus drug, epratuzumab, has failed to meet primary endpoints in two Phase III trials – an event which could deter future investment from this historically tricky development space.
You may also be interested in...
Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way for new treatments for a disease with few options. Experts say they are energized by the amount of investment in lupus R&D.
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2021. Data provided by Biomedtracker.
Catherine Owen joined Bristol Myers Squibb in September 2019, tasked with overseeing the integration of Celgene and BMS’s international businesses. She talks to In Vivo about managing the merger of teams from two very distinct companies during a global pandemic. Owen, who is passionate about career growth and mentoring, also highlights the importance of talent development and sponsorship – even in times of uncertainty, when business as usual goes out the window.